Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation.
Complement receptor type 2 (CR2) is a receptor that serves as an important interface between the complement system and adaptive immunity. Recent studies have shown that CR2 is also centrally involved in innate immunity, and one key area is the development of potentially pathogenic natural antibodies that target neo-epitopes revealed in ischemic tissue undergoing reperfusion. Mice lacking either total immunoglobulins or CR2 alone are protected from the development of ischemia-reperfusion injury, and this effect can be reversed by introducing CR2-sufficient B-1 cells or by transferring polyclonal natural IgM antibody from wild type mice as well as monoclonal antibodies that recognize phospholipids, DNA or non-muscle myosin. We will report at the XXI ICW an additional membrane-associated protein to which pathogenic IgM antibodies are directed. Whether B cells producing these natural antibodies are differentially selected in CR2-deficient mice is as yet not well understood, and the complement-related mechanism(s) whereby this differential repertoire selection process could occur have yet to be explored in any detail. In addition to this important role in innate immunity, CR2 can also act as a receptor for other components or activators of innate immunity. One such component is interferon-alpha, an anti-viral cytokine that binds CR2 and induces a component of its mRNA signature in B cells through this receptor. Other potential CR2 ligands are DNA and DNA-containing complexes such as chromatin. The biologic role of these CR2 interactions with interferon-alpha and DNA-containing complexes is not well understood, but may be important in the development of the autoimmune disease systemic lupus erythematosus that is characterized by enhanced interferon-alpha levels and loss of self tolerance to DNA-containing self antigens.
Holers
V Michael
VM
Department of Immunology, University of Colorado Health Sciences Center, Denver, CO 80262, USA. michael.holers@uchsc.edu
Kulik
Liudmila
L
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D015551:Autoimmunity; D001402:B-Lymphocytes / Q000276:immunology*; D004247:DNA / Q000378:metabolism; D000939:Epitopes; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000378:metabolism; D008213:Lymphocyte Activation; D011947:Receptors, Antigen, B-Cell / Q000502:physiology; D017464:Receptors, Complement 3d / Q000502:physiology*
D000906:Antibodies; D000939:Epitopes; D016898:Interferon-alpha; D011947:Receptors, Antigen, B-Cell; D017464:Receptors, Complement 3d; D004247:DNA